Related Experiment Videos
Angiostatin expression in non-small cell lung cancer
1Department of Oncological Diagnostics and Therapy, German Cancer Research Center, Heidelberg.
Summary
Angiostatin, an angiogenesis inhibitor, was found in 24% of non-small cell lung cancer tumors. Higher angiostatin levels correlated with longer patient survival, especially when combined with low vascular endothelial growth factor (VEGF).
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Angiostatin is a known inhibitor of angiogenesis, tumor growth, and metastasis.
- Understanding prognostic markers in non-small cell lung cancer (NSCLC) is crucial for patient outcomes.
Purpose of the Study:
- To investigate the presence and prognostic significance of angiostatin in primary NSCLC.
- To evaluate the combined prognostic value of angiostatin and vascular endothelial growth factor (VEGF) in NSCLC.
Main Methods:
- Western blot analysis of human lung cancer cell lines.
- Immunohistochemistry on 143 primary non-small cell lung carcinomas.
- Correlation analysis between protein expression and patient survival data.
Main Results:
- Angiostatin positivity was observed in 24% of NSCLC cases.
- Patients with angiostatin-positive tumors showed significantly longer survival than those with negative tumors (146 vs. 77 weeks).
- Combined analysis revealed median survival of 184 weeks for angiostatin-positive/VEGF-negative tumors versus 52 weeks for angiostatin-negative/VEGF-positive tumors.
Conclusions:
- Angiostatin expression is a potential positive prognostic marker in non-small cell lung cancer.
- The combination of angiostatin and VEGF status offers improved prognostic capability for NSCLC patients.
- Angiostatin-positive tumors may exhibit reduced metastatic potential, indicated by increased apoptosis and lower transplantability.